Advertisement
help button home button The Oncologist
HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
The Oncologist, Vol. 11, No. 6, 630-640, June 2006; doi:10.1634/theoncologist.11-6-630
© 2006 AlphaMed Press

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow eLetters: Submit a response to this article
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Reprints/Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Cohen, S. M.
Right arrow Articles by Grossbard, M. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cohen, S. M.
Right arrow Articles by Grossbard, M. L.

Genitourinary Cancer

The Role of Perioperative Chemotherapy in the Treatment of Urothelial Cancer

Seth M. Cohena,e, Anupama Goela,e, John Phillipsd,e, Ronald D. Ennisa,b,e, Michael L. Grossbarda,c,e

a Department of Medicine, Division of Hematology/Oncology and b Department of Radiation Oncology, St. Luke’s-Roosevelt Hospital Center, New York, New York, USA; c Department of Medicine, Division of Hematology/Oncology and d Department of Urology, Beth Israel Medical Center, New York, New York, USA; e Continuum Cancer Centers of New York, New York, New York, USA

Key Words. Urothelial cancer • Transitional cell carcinoma • Neoadjuvant • Adjuvant • Chemotherapy

Correspondence: Seth M. Cohen, M.D., St. Luke’s-Roosevelt Hospital Center, 1000 Tenth Avenue 11C-02, New York, New York 10019, USA. Telephone: 212-523-6705; Fax: 212-523-2004; e-mail secohen{at}chpnet.org

Cancer of the urothelium is the fourth most common malignancy in men in the U.S. and the ninth most common in women. More than 63,000 Americans will be diagnosed with bladder cancer this year (47,010 men and 16,200 women), and more than 13,000 (8,970 men and 4,210 women) can expect to die of their disease. The approximate 5:1 ratio of incidence to mortality roughly parallels the frequency of superficial to invasive disease. Efforts to improve this ratio have generated a potential paradigm shift in the treatment of urothelial cancer, incorporating increasingly active chemotherapy into treatment regimens for high-risk tumors in both the pre-and postoperative settings. This review summarizes the evolution of chemotherapeutic treatment of urothelial cancer and the rationale for its perioperative administration and addresses the future directions of clinical research in this field.






HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
THE ONCOLOGIST STEM CELLS CME ALPHAMED PRESS JOURNALS


Copyright © 2006 by AlphaMed Press.
Advertisement